Lam Research (NASDAQ:LRCX) Shares Up 2.4% – Still a Buy?

Shares of Lam Research Corporation (NASDAQ:LRCX) were up 2.4% during mid-day trading on Monday . The company traded as high as $166.87 and last traded at $164.30. Approximately 10,109,431 shares changed hands during mid-day trading, a decline of 14% from the average daily volume of 11,744,850 shares. The stock had previously closed at $160.52.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Evercore ISI boosted their price target on shares of Lam Research from $115.00 to $170.00 and gave the company an “outperform” rating in a report on Thursday, October 23rd. Jefferies Financial Group reissued a “buy” rating and set a $200.00 target price (up from $175.00) on shares of Lam Research in a research note on Monday. Deutsche Bank Aktiengesellschaft upped their target price on shares of Lam Research from $150.00 to $160.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Lam Research in a report on Monday, December 8th. Finally, Stifel Nicolaus set a $160.00 price objective on Lam Research and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Twenty-six research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $156.21.

Lam Research Trading Up 2.4%

The business’s 50 day moving average price is $152.53 and its two-hundred day moving average price is $120.50. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.60 and a current ratio of 2.21. The company has a market capitalization of $206.37 billion, a price-to-earnings ratio of 36.19, a price-to-earnings-growth ratio of 1.65 and a beta of 1.77.

Lam Research (NASDAQ:LRCX) last released its earnings results on Wednesday, October 22nd. The semiconductor company reported $1.26 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.04. Lam Research had a return on equity of 60.60% and a net margin of 29.66%.The firm had revenue of $5.32 billion during the quarter, compared to the consensus estimate of $5.23 billion. During the same period in the prior year, the firm posted $0.86 earnings per share. The firm’s revenue for the quarter was up 27.7% compared to the same quarter last year. Lam Research has set its Q2 2026 guidance at 1.050-1.250 EPS. Equities analysts forecast that Lam Research Corporation will post 3.71 earnings per share for the current fiscal year.

Lam Research Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 7th. Shareholders of record on Wednesday, December 3rd will be given a $0.26 dividend. The ex-dividend date is Wednesday, December 3rd. This represents a $1.04 annualized dividend and a yield of 0.6%. Lam Research’s payout ratio is 22.91%.

Insider Buying and Selling

In related news, CFO Douglas R. Bettinger sold 40,080 shares of Lam Research stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $150.60, for a total value of $6,036,048.00. Following the transaction, the chief financial officer owned 987,237 shares of the company’s stock, valued at approximately $148,677,892.20. This trade represents a 3.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Vahid Vahedi sold 52,190 shares of the business’s stock in a transaction dated Monday, October 13th. The stock was sold at an average price of $138.90, for a total value of $7,249,191.00. Following the sale, the senior vice president owned 251,047 shares in the company, valued at approximately $34,870,428.30. The trade was a 17.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 102,608 shares of company stock worth $14,916,496 over the last quarter. 0.31% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Lam Research

Several institutional investors and hedge funds have recently added to or reduced their stakes in LRCX. Brighton Jones LLC boosted its position in Lam Research by 1,032.4% during the 4th quarter. Brighton Jones LLC now owns 14,189 shares of the semiconductor company’s stock worth $1,025,000 after acquiring an additional 12,936 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Lam Research during the first quarter worth approximately $245,000. EverSource Wealth Advisors LLC grew its position in Lam Research by 39.8% during the first quarter. EverSource Wealth Advisors LLC now owns 5,916 shares of the semiconductor company’s stock valued at $430,000 after purchasing an additional 1,685 shares in the last quarter. American Century Companies Inc. increased its stake in Lam Research by 25.3% in the 1st quarter. American Century Companies Inc. now owns 1,637,458 shares of the semiconductor company’s stock valued at $119,043,000 after buying an additional 330,629 shares during the period. Finally, Raymond James Financial Inc. grew its holdings in shares of Lam Research by 94.6% during the 1st quarter. Raymond James Financial Inc. now owns 2,882,196 shares of the semiconductor company’s stock valued at $209,535,000 after acquiring an additional 1,401,409 shares in the last quarter. 84.61% of the stock is currently owned by hedge funds and other institutional investors.

About Lam Research

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.